List view / Grid view

Dr Bryan Oronsky (EpicentRx)

 

article

Therapeutic frontiers: the potential of RRx-001 and AdAPT-001

Meet RRx-001 (nibrozetone) and AdAPT-001—two cutting-edge compounds crafted by EpicentRx.…

25 August 2023 | By

Meet RRx-001 (nibrozetone) and AdAPT-001—two cutting-edge compounds crafted by EpicentRx. In this Q&A session with Dr Bryan Oronsky, Chief Development Officer at EpicentRx, we discover novel mechanisms, diverse applications, and game-changing impact on cancer treatment and beyond.